Clinical trials: EGFR Mutant
NSCLC Stage IV, EGFR Gene Mutation
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
STEREO is single-arm phase II study, which aims to evaluate the safety and efficacy of osimertinib combined with early locally ablative radiotherapy of all cancer sites in patients with synchronous oligo-metastatic (primary…
- Trial name
- STEREO (NCT04908956)
- Testing
- Osimertinib, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 18 sites in Italy, Netherlands and 6 more
- Volunteers
- 6 people
- Sponsor
- ETOP IBCSG Partners Foundation
Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study
Lung cancer still occupies the highest incidence and mortality rate in the wordwild, and non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of all lung cancers.
- Trial name
- NCT04517526
- Testing
- pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Cancer Hospital, China
Locally Advanced or Metastatic NSCLC
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
This is a phase 2 single-arm, non-randomized multicentre and tissue acquisition study to evaluate acquired resistance mechanisms, efficacy, and safety in advanced, EGFR tyrosine kinase inhibitor-naïve NSCLC patients with…
- Trial name
- NCT03969823
- Testing
- Tagrisso
- Where
- 3 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Seoul National University Hospital
Glioblastoma, IDH-Wildtype
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma.
- Trial name
- NCT07708961
- Testing
- Archive Sample Retrieval, Biospecimen Collection, Chest Radiography
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
- Trial name
- NCT01719380
- Testing
- LGX818, Cetuximab, BYL719
- Where
- 52 sites in United States, Australia and 10 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Brain Metastases
Central Nervous System(CNS) Efficacy of Dacomitinib
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
- Trial name
- NCT04675008
- Testing
- Dacomitinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Lung Cancer (NSCLC)
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Background Synchronous multifocal primary lung cancer (sMPLC) presents a therapeutic challenge, particularly for bilateral lesions.
- Trial name
- ARMOR2501 (NCT06924398)
- Testing
- Postoperative EGFR-TKI Therapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations.
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03410043
- Testing
- Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- 4 sites in United States
- Volunteers
- 173 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer Metastatic, EGFR Gene Mutation
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer.
- Trial name
- NCT04085315
- Testing
- Osimertinib, Alisertib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Collin Blakely
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS…
- Trial name
- NCT07143045
- Testing
- zorifertinib
- Where
- 34 sites in China
- Volunteers
- 800 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Carcinoma, Non-Small Cell Lung
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with…
- Trial name
- Acclaim-1 (NCT04486833)
- Testing
- quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Genprex, Inc.
NSCLC (Non-small Cell Lung Carcinoma), Stage III
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
This is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive…
- Conditions
- NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations
- Trial name
- NCT07314216
- Testing
- Firmonertinib, Definitive Thoracic Radiotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hunan Cancer Hospital
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or…
- Trial name
- NCT07680790
- Testing
- Iza-bren, Osimertinib, Pemetrexed
- Where
- 204 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer (NSCLC)
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT06585644
- Testing
- Furmonertinib in combination with Anrotinib and chemotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
The objective of this study is to determine best overall response rate (BOR) based on radiological assessment per RECIST v1.1 to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.
- Trial name
- NCT05773092
- Testing
- Oral S-1 + Oral Osimertinib
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Carcinoma, Non-Small-Cell Lung
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
- Trial name
- REVEAL (NCT03761901)
- Testing
- 1L treatment, 2L Treatment, 3L treatment
- Where
- 15 sites in Belgium
- Volunteers
- 141 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Leptomeningeal metastasis (LM) is a complication of advanced non-small cell lung cancer (NSCLC). The incidence of LM in NSCLC patients is around 3-5 %, reaching 9.4 % of those with an epidermal growth factor receptor (EGFR)…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis
- Trial name
- NCT05805631
- Testing
- Pemetrexed
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Lung Cancer
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: EGF816 Gefitinib
- Trial name
- NCT03292133
- Testing
- EGF816, Gefitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer
Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.
- Trial name
- REMNANT (NCT02470065)
- Testing
- Afatinib, Immediate surgery
- Volunteers
- 38 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer (NSCLC)
e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer
The purpose of this study is to develop a real-time diagnostic technique with e- Ab sensor for specific EGFR mutation detection in clinical specimens of NSCLC patients, the investigators conduct a prospective clinical study.
- Trial name
- NCT01359436
- Testing
- Electrosensing antibody probing system (e- Ab sensing)
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital